Author(s): ZHOU Zewei, LIU Peixun, LI Songnian, XU Wenqing, ZHANG Heqing, WANG Yueying, LIU Zhengming
Pages: 990-991
Year: 2004 Issue:  5
Journal: CHINESE JOURNAL OF CLINICAL REHABILITATION
Keyword:  乳腺肿瘤; 抗肿瘤剂(中药); 小鼠; 淋巴瘤;
Abstract: AIM: To investigate the inhibiting effects of 9002#, a derivative of alkaloids from Sophora alopecrokdes, on lymphoma and mammary adenoma. METHODS: Sixty-three IRM-2 inbred strain mice were inoculated with lymphoma and mammary adenoma respectively. 9002#, at the doses of 50 mg/kg per day × 10 days and 150 mg/kg per day × 10 days were injected intraperitoneally. The changes of body mass and tumor mass were scaled, and the inhibiting rates were analyzed. RESULTS: The lymphoma-inhibiting rate of 9002# at the dosage of 50 mg/kg once a day×10 days was 51.3% -53.5% (t=4.04, 3.30, P ＜0.01), and that of 9002# at the dosage of 150 mg/kg once a day × 10 days was 31.3%-35.7% (t=2.22, 2.49, P ＜ 0.05). The mammary adenoma-inhibiting rate of 9002# at the dosage of 50 mg/kg once a day × 10 days was 57.1% ( t = 2.63, P ＜ 0.01 ), and that of 9002# at the dosage of 150 mg/kg once a day × 10 days was 48.6% (t= 2.19, P＜0.01). CONCLUSION: 9002# has certain inhibiting effects on transplanting sarcomas in IRM-2 inbred strain mice, and the drug at the dosage 50 mg/kg once a day × 10 days is more effective on both sarcomas. 9002# has potential value in clinical cancer treatment.